Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor
Interventions: DRUG: CX-5461
Sponsor: Senhwa Biosciences, Inc.